United Therapeutics Corporation Cost-method Investments, Other than Temporary Impairment
United Therapeutics Corporation (UTHR) reported Cost-method Investments, Other than Temporary Impairment of $49.60 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CostmethodInvestmentsOtherThanTemporaryImpairment · last filed 2018-02-21
- United Therapeutics Corporation cost-method investments, other than temporary impairment for the quarter ending 2017-12-31 was $0.00.
- United Therapeutics Corporation cost-method investments, other than temporary impairment for the quarter ending 2017-09-30 was $3.10M.
- United Therapeutics Corporation cost-method investments, other than temporary impairment for the quarter ending 2017-06-30 was $46.50M.
- United Therapeutics Corporation cost-method investments, other than temporary impairment for the quarter ending 2017-03-31 was $0.00.
- United Therapeutics Corporation cost-method investments, other than temporary impairment for fiscal 2017 was $49.60M.
| Period end | Cost-method Investments, Other than Temporary Impairment 3 month | Cost-method Investments, Other than Temporary Impairment 6 month | Cost-method Investments, Other than Temporary Impairment 9 month | Cost-method Investments, Other than Temporary Impairment 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $3.10M derived: sum of 2 quarters · filed 2018-02-21 | $49.60M derived: sum of 3 quarters · filed 2018-02-21 | $49.60M 10-K · filed 2018-02-21 |
| 2017-09-30 | $3.10M 10-Q · filed 2017-10-25 | $49.60M derived: sum of 2 quarters · filed 2017-10-25 | $49.60M 10-Q · filed 2017-10-25 | |
| 2017-06-30 | $46.50M 10-Q · filed 2017-07-27 | $46.50M 10-Q · filed 2017-07-27 | ||
| 2017-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2018-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |